# Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms

> **NCT06786936** · — · RECRUITING · sponsor: **NHS Greater Glasgow and Clyde** · enrollment: 50 (estimated)

## Conditions studied

- Psoriatic Arthritis
- Depression
- Psoriatic Plaque

## Interventions

- **DRUG:** Secukinumab
- **DRUG:** Bimekizumab
- **DRUG:** Ixekizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06786936
- **Lead sponsor:** NHS Greater Glasgow and Clyde
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-02
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-04-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-06-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06786936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06786936, "Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06786936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*